A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects With Androgenetic Alopecia (AGA)
Latest Information Update: 16 Mar 2023
At a glance
- Drugs TDM-105795 (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors TechnoDerma Medicines
- 13 Mar 2023 Status changed from recruiting to completed.
- 26 Apr 2022 Status changed from not yet recruiting to recruiting.
- 21 Feb 2022 New trial record